Recombinant Human E2F1/RBBP3 Protein, N-His from ProteoGenix; catalogue ARO-P12747; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Human E2F1/RBBP3 Protein, also known as retinoblastoma binding protein 3 (RBBP3), is a highly conserved protein that plays a crucial role in cell cycle regulation and DNA repair. It is a member of the E2F family of transcription factors and is involved in the transcriptional activation of genes required for cell proliferation. This protein is produced through recombinant DNA technology and has a wide range of applications in both research and therapeutic settings.
Recombinant Human E2F1/RBBP3 Protein is a 118 kDa protein consisting of 1052 amino acids. It contains a conserved E2F DNA-binding domain, a retinoblastoma-binding domain, and a transcriptional activation domain. The protein also has several phosphorylation sites, which regulate its activity and function.
Recombinant Human E2F1/RBBP3 Protein is a transcription factor that plays a key role in regulating the cell cycle. It binds to specific DNA sequences and activates the transcription of genes involved in cell proliferation, DNA replication, and repair. This protein is also involved in chromatin remodeling, which is essential for the proper functioning of the cell cycle.
In addition to its role in cell cycle regulation, Recombinant Human E2F1/RBBP3 Protein has been shown to have anti-apoptotic activity. It can protect cells from undergoing programmed cell death by inhibiting the expression of pro-apoptotic genes. This makes it a potential target for cancer therapy, as many cancer cells have defects in their apoptotic pathways.
Recombinant Human E2F1/RBBP3 Protein has a wide range of applications in both research and therapeutic settings. In research, it is commonly used as a tool to study the cell cycle and its regulation. Its ability to activate the transcription of cell cycle genes makes it a valuable tool for understanding the molecular mechanisms involved in cell proliferation.
In therapeutic settings, Recombinant Human E2F1/RBBP3 Protein has shown promise as a potential target for cancer therapy. Its anti-apoptotic activity and role in cell cycle regulation make it an attractive target for drugs that can selectively kill cancer cells while sparing normal cells. Additionally, this protein has been implicated in the development of drug resistance in cancer cells, making it a potential target for overcoming resistance to chemotherapy.
Furthermore, Recombinant Human E2F1/RBBP3 Protein has been studied for its potential role in neurodegenerative diseases. It has been shown to protect neurons from oxidative stress and promote their survival, making it a potential therapeutic target for diseases such as Alzheimer’s and Parkinson’s.
Recombinant Human E2F1/RBBP3 Protein is a crucial protein involved in cell cycle regulation and DNA repair. Its structure, activity, and various applications make it a valuable tool in research and a potential target for therapeutic interventions. Further studies on this protein may uncover its full potential and lead to the development of novel treatments for various diseases, including cancer and neurodegenerative disorders.
ProteoGenix catalogue number ARO-P12747. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 40.94 kDa; Fragment: Val88-Phe437; Buffer: 0.01M PBS, pH 7.4..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
